Global vaccine-sharing network Covax is still seeing strong demand for India-made doses of the AstraZeneca Covid-19 shot, its co-lead Gavi said, following comments from producer Serum Institute of India (SII) that uptake had slowed sharply.
Gavi said Covax had allocated 40 million Covishield doses to countries after New Delhi last month let the SII resume such supplies for the first time since April, and that it had the option to buy vaccines keeping a “flexible approach as the pandemic and countries' needs continue to evolve”.
“We are still experiencing robust country demand for SII-Covishield ...” a Gavi spokesperson said in an email to Reuters.
